Literature DB >> 19189211

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.

Sharon Nofech-Mozes1, Maureen Trudeau, Harriet K Kahn, Rebecca Dent, Ellen Rawlinson, Ping Sun, Steven A Narod, Wedad M Hanna.   

Abstract

Traditional prognostic markers for breast cancer include estrogen receptor (ER), progesterone receptor (ER) and HER2/neu. Negative staining for these three markers defines the 'triple-negative' phenotype. By adding markers for cytokeratin 5/6 and EGFR, triple-negative breast cancers can be divided into 'basal-like' and 'normal-like' subgroups. We conducted immuno-staining on a panel of 958 patients with breast cancer, using all five markers and we followed the patients for distal recurrence and death. We compared rates of distal recurrence in the basal-like and normal-like subgroups with that of women with ER-positive breast cancer. Only 16 of 958 women had normal-like breast cancers. These cancers resembled basal-like cancers in that they had a high proliferative index, but the women with normal-like breast cancers resembled ER-positive women in terms of distant recurrence. The addition of CK5/6 and EGFR to the standard panel (ER/PR/HER2/neu) defines a small subgroup of women with normal-like breast cancer. The prognosis of these women may be superior to that of basal-like breast cancers but firm conclusions cannot be made.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189211     DOI: 10.1007/s10549-008-0295-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  39 in total

1.  Triple-negative breast cancer is not a contraindication for breast conservation.

Authors:  Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam
Journal:  Ann Surg Oncol       Date:  2011-09-27       Impact factor: 5.344

2.  Cancer progression modeling using static sample data.

Authors:  Yijun Sun; Jin Yao; Norma J Nowak; Steve Goodison
Journal:  Genome Biol       Date:  2014-08-26       Impact factor: 13.583

3.  Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers.

Authors:  Chi-Chen Hong; Song Yao; Susan E McCann; Ree Y Dolnick; Paul K Wallace; Zhihong Gong; Lei Quan; Kelvin P Lee; Sharon S Evans; Elizabeth A Repasky; Stephen B Edge; Christine B Ambrosone
Journal:  Breast Cancer Res Treat       Date:  2013-04-30       Impact factor: 4.872

4.  PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.

Authors:  A Paul; S Gunewardena; S R Stecklein; B Saha; N Parelkar; M Danley; G Rajendran; P Home; S Ray; I Jokar; G A Vielhauer; R A Jensen; O Tawfik; S Paul
Journal:  Cell Death Differ       Date:  2014-05-02       Impact factor: 15.828

5.  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Authors:  Kristen S Purrington; Susan Slager; Diana Eccles; Drakoulis Yannoukakos; Peter A Fasching; Penelope Miron; Jane Carpenter; Jenny Chang-Claude; Nicholas G Martin; Grant W Montgomery; Vessela Kristensen; Hoda Anton-Culver; Paul Goodfellow; William J Tapper; Sajjad Rafiq; Susan M Gerty; Lorraine Durcan; Irene Konstantopoulou; Florentia Fostira; Athanassios Vratimos; Paraskevi Apostolou; Irene Konstanta; Vassiliki Kotoula; Sotiris Lakis; Meletios A Dimopoulos; Dimosthenis Skarlos; Dimitrios Pectasides; George Fountzilas; Matthias W Beckmann; Alexander Hein; Matthias Ruebner; Arif B Ekici; Arndt Hartmann; Ruediger Schulz-Wendtland; Stefan P Renner; Wolfgang Janni; Brigitte Rack; Christoph Scholz; Julia Neugebauer; Ulrich Andergassen; Michael P Lux; Lothar Haeberle; Christine Clarke; Nirmala Pathmanathan; Anja Rudolph; Dieter Flesch-Janys; Stefan Nickels; Janet E Olson; James N Ingle; Curtis Olswold; Seth Slettedahl; Jeanette E Eckel-Passow; S Keith Anderson; Daniel W Visscher; Victoria L Cafourek; Hugues Sicotte; Naresh Prodduturi; Elisabete Weiderpass; Leslie Bernstein; Argyrios Ziogas; Jennifer Ivanovich; Graham G Giles; Laura Baglietto; Melissa Southey; Veli-Matti Kosma; Hans-Peter Fischer; Malcom W R Reed; Simon S Cross; Sandra Deming-Halverson; Martha Shrubsole; Qiuyin Cai; Xiao-Ou Shu; Mary Daly; Joellen Weaver; Eric Ross; Jennifer Klemp; Priyanka Sharma; Diana Torres; Thomas Rüdiger; Heidrun Wölfing; Hans-Ulrich Ulmer; Asta Försti; Thaer Khoury; Shicha Kumar; Robert Pilarski; Charles L Shapiro; Dario Greco; Päivi Heikkilä; Kristiina Aittomäki; Carl Blomqvist; Astrid Irwanto; Jianjun Liu; Vernon Shane Pankratz; Xianshu Wang; Gianluca Severi; Arto Mannermaa; Douglas Easton; Per Hall; Hiltrud Brauch; Angela Cox; Wei Zheng; Andrew K Godwin; Ute Hamann; Christine Ambrosone; Amanda Ewart Toland; Heli Nevanlinna; Celine M Vachon; Fergus J Couch
Journal:  Carcinogenesis       Date:  2013-12-09       Impact factor: 4.944

6.  Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy.

Authors:  Lisa D Volk-Draper; Sandeep Rajput; Kelly L Hall; Andrew Wilber; Sophia Ran
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 7.  Genomic profiling in triple-negative breast cancer.

Authors:  Cornelia Liedtke; Christof Bernemann; Ludwig Kiesel; Achim Rody
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

8.  Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.

Authors:  Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-26

Review 9.  Genetic susceptibility to triple-negative breast cancer.

Authors:  Kristen N Stevens; Celine M Vachon; Fergus J Couch
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

10.  Triple negative breast cancer - our experience and review.

Authors:  S Krishnamurthy; R Poornima; Vasu Reddy Challa; Y G Basavana Goud
Journal:  Indian J Surg Oncol       Date:  2012-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.